LexDanaLexDanabeta
New SessionDrug SearchOfficial RankingsInsights
© LexDana · beta
LexDanaLexDanabeta
New SessionDrug SearchOfficial RankingsInsights
LexDanaLexDanabeta

Insights

Analysis of patent litigation, PTAB practice, prosecution and pharma IP, written on the data behind LexDana.

AllCopyright & Trade Secrets59Federal Circuit877ITC / Section 33788Patent Litigation216Patent Prosecution126Pharma & ANDA62PTAB686Supreme Court61Trademark158USPTO Policy78Unsorted257

Tagged central reexamination unit · clear

PTAB

Thwart PTAB Attacks With These USPTO Post-Grant Options

CRU Faster Than Before AIA, Provides Options for Patent Owners Patent reexamination filings have fallen 86% since 2012. With the elimination of the popular inter partes patent reexamination option in 2012, an overall decrease was certainly expected.…

January 31, 2018·PTAB·3 min read
Data: FDA Orange & Purple Books · prosecution & litigation metadata · read-only.